The most complete commentary available on the state of patent law. This monumental reference places federal patent law decisions, both high-profile and less-celebrated, into an analytical framework that demonstrates their relevance and impact. It details the ever-changing issues and developments in substantive patent law, infringement litigation, and procedure.
This monumental reference deals with both the high-profile cases and the “uncelebrated decisions” that tend to slip under the radar and fits them into an analytical framework that reveals their true significance. Patents and the Federal Circuit addresses ever-changing issues and developments in substantive patent law, infringement litigation, and procedure. The authors distill the opinions issued by the primary source of governing law on patents, providing convenient, one-source access to controlling case law.
The Twelfth Edition includes discussion of the following:
The U.S. Supreme Court’s decision in Cuozzo Speed Technologies, LLC v. Lee, holding that the PTO’s decision to institute inter partes review is final and appealable and that the PTO properly construes claims in inter partesreview proceedings according to their broadest reasonable interpretation.
The Supreme Court’s decision in Halo Electronics, Inc. v. Pulse Electronics overruling the Federal Circuit’s application of a two-part test for determining when a court may increase damages under 35 U.S.C. §284.
The Federal Circuit’s ruling in Ariosa Diagnostics, Inc. v. Sequenom, Inc., holding that claims covering a multistep method for extracting and analyzing fetal DNA to determine inherited fetal characteristics, including identification of genetic defects, were unpatentable subject matter under 35 U.S.C. §101 because the claims were merely an application that began and ended with a naturally occurring phenomenon.
The Federal Circuit’s en banc ruling on remand from the Supreme Court in Akamai Technologies Inc. v. Limelight Networks, Inc. holding that the predicate act for direct infringement in a scenario involving multiple actors occurs where all method steps can be attributed to a single entity. Under this standard, direct infringement by multiple actors is no longer limited to situations involving principal-agent relationships, contractual arrangements, or joint enterprises.
The Federal Circuit’s first ruling involving the Biologics Price Competition and Innovation Act of 2009 (BPCIA) in Amgen v. Sandoz, which clarifies the procedures and standards for notice and commercial marketing under the BPCIA.
The Federal Circuit’s ruling in Dow Chem. Co. v. Nova Chems. Corp. (Can.) where the court addressed the definiteness requirement in the aftermath of the Supreme Court’s decision in NautilusInstruments v. Biosig.
The Federal Circuit’s ruling in Dome Patent L.P. v. Lee holding that the presumption of validity and the clear and convincing standard of proof required to overcome the presumption do not apply in PTO’s patentability determinations.
The Federal Circuit’s decision in Versata Dev. Grp., Inc. v. SAP Am., Inc., where the court explored what constitutes a covered business method patent under the America Invents Act (AIA).
The Federal Circuit’s ruling in Delano Farms Co. v. Cal. Table Grape Comm’n holding that an agreement of confidentiality, or circumstances creating a similar expectation of secrecy, may negate a public use where there is not commercial exploitation.
The Federal Circuit’s first decisions applying the modified standard of review for claim construction set out in the Supreme Court’s 2014 Teva v. Sandoz decision, including the Federal Circuit’s decisions on remand from the Supreme Court in Lighting Ballast Control LLC v. Philips Elecs. N. Am. Corp. and Teva Pharms. USA, Inc. v. Sandoz, Inc.
The Federal Circuit’s ruling in Speedtrack, Inc. v. Office Depot, Inc. holding that a customer may assert the Kessler doctrine as a defense in an infringement suit where the customer’s supplier has been adjudicated not to infringe.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)